Lantern Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
LTRN Nasdaq 8731 https://www.lanternpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lantern Pharma Inc

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development - Apr 24th, 2024 12:00 pm
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan - Apr 22nd, 2024 12:12 pm
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript - Mar 19th, 2024 1:06 pm
LTRN: 2023 Results - Mar 19th, 2024 12:49 pm
Lantern Pharma Inc Reports Progress and Financials for FY 2023 - Mar 18th, 2024 9:32 pm
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights - Mar 18th, 2024 8:02 pm
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 - Mar 15th, 2024 12:00 pm
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET - Mar 11th, 2024 11:30 am
11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds - Mar 7th, 2024 11:17 am
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Mar 5th, 2024 1:01 pm
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines - Mar 4th, 2024 1:01 pm
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom - Feb 20th, 2024 1:01 pm
LTRN: Spotlighting ADCs & Another Orphan - Feb 20th, 2024 10:48 am
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers - Feb 15th, 2024 1:01 pm
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Feb 5th, 2024 4:33 pm
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer - Jan 17th, 2024 12:30 pm
The 3 Most Undervalued AI Penny Stocks to Buy in December - Dec 13th, 2023 1:05 pm
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) - Nov 30th, 2023 1:00 pm
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript - Nov 10th, 2023 4:31 pm
LTRN: Three Assets in the Clinic in 3Q:23 - Nov 9th, 2023 10:18 am